Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib
Cancer Treatment Communications · 2014
DOI: 10.1016/j.ctrc.2014.03.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment Communications, 2014. Verfasst von C. Leitner und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).
Abstract (Originalsprache)
We report a case of a 59-year-old woman with brain metastases from an EGFR mutated adenocarcinoma of the lung. She was initially treated with erlotinib and two times whole brain radiation therapy. After a second relapse within the CNS the therapy was switched to gefitinib and a partial remission of the brain metastases could be achieved. Our case demonstrates that patients can respond to a switch of the EGFR TKI also within the CNS despite heavy pre-treatment. The article reviews the literature regarding the efficacy of tyrosine kinase inhibitors in brain metastases from lung cancers.
Zitieren
APA
Leitner, C., Moos, R. V., Mark, M., Früh, M., & Cathomas, R. (2014). Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib. Cancer Treatment Communications. https://doi.org/10.1016/j.ctrc.2014.03.001
Vancouver
Leitner C, Moos RV, Mark M, Früh M, Cathomas R. Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib. Cancer Treatment Communications. 2014. doi:10.1016/j.ctrc.2014.03.001
BibTeX
@article{Leitner2014,
author = {Leitner, C. and Moos, R. von and Mark, M. and Früh, M. and Cathomas, R.},
title = {Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib},
journal = {Cancer Treatment Communications},
year = {2014},
doi = {10.1016/j.ctrc.2014.03.001}
}
EUVIMED